All In Biotech

Drug Trial Radar · NCT04481607

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

Last checked: Nov 19, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

96

Planned (sponsor's estimate)

Start

Aug 24, 2020

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Sponsor type
Industry
First posted
Jul 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.

Conditions

  • Advanced Solid Tumor or Hematologic Tumor

Interventions

  • TQB3454Drug

    TQB3454 tablets is a small molecule oral drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: Baseline up to 28 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Affiliated Hosptial of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Tianjing Medical University Cancer Institute&Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Hematology Hospital of Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hosptial Zhejiang University School of Medical

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.